Safinamide Mesylate

Safinamide mesylate is a monoamine oxidase B inhibitor.

Safinamide mesylate has the following uses:

Safinamide mesylate is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing “off” episodes.1

Safinamide mesylate has the following limitations of use:

Safinamide mesylate has not been shown to be effective as monotherapy for the treatment of Parkinson's disease.1

AHFS First Release. For additional information until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is essential that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.